<DOC>
	<DOC>NCT01689831</DOC>
	<brief_summary>Dose comparison study of tuberculin purified protein derivative (PPD)Aplisol with the standard tuberculin purified derivative (PPD-S2).</brief_summary>
	<brief_title>Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)</brief_title>
	<detailed_description>JHP proposes to demonstrate clinical comparability of Aplisol formulated from the new Tuberculin PPD drug substance to the standard PPD-S2.</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1. Males or nonpregnant females age 18 to 60 years 2. Documented PPD reactivity of 5 to 21 mm in the past, documented in a medical record. Selfreported PPD reactivity will be accepted if medical records cannot be obtained. 3. Give written informed consent to participate 4. Generally healthy, as determined by medical history and targeted physical examination, if indicated 5. Possess 2 forearms that are free of burns, scars, eczema, or any physical deformity, which could impair injection of study preparation or the readings of the injections 6. Comprehension of the study requirements; expressed availability for the required study period, including readings at the nominal time points of 48 and 72 hours 1. Prior PPD test within the past 30 days 2. Subject is of childbearing potential and unable to use contraceptives; is planning pregnancy; is pregnant or lactating 3. History of anaphylactic reaction, severe positive tuberculin reaction (eg, ulceration, necrosis) or other severe reaction to PPD in the past 4. Subject received a Bacillus CalmetteGu√©rin (BCG) vaccination in the past, or was born or lived outside the US as a child and is uncertain of his/her BCG vaccination status 5. Presence of conditions that may suppress TST reactivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>